<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aarti Asnani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tomas G Neilan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Debasish Tripathy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marielle Scherrer-Crosbie, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H984439790"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The anthracyclines and related compounds (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a>, <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, and the anthraquinone <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>) are among the chemotherapeutic agents implicated in cardiotoxicity. Most commonly, anthracycline therapy is associated with left ventricular (LV) systolic dysfunction due to myocyte damage and replacement by fibrous tissue [<a href="#rid1">1</a>].</p><p>The clinical manifestations, diagnosis, management, and prognosis of anthracycline-induced cardiotoxicity will be reviewed here.</p><p>The mechanisms, risk factors, and approach to prevention of anthracycline cardiotoxicity and the cardiovascular complications of anthracyclines are presented separately. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p>The cardiotoxicity of other classes of chemotherapy agents is discussed separately. (See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a> and  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a> and  <a class="medical medical_review" href="/d/html/89348.html" rel="external">"Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical manifestations, mechanisms, and management"</a>.)</p><p class="headingAnchor" id="H3033830258"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1021906244"><span class="h2">Specific presentations</span><span class="headingEndMark"> — </span>The clinical manifestations of anthracycline toxicity are primarily those of heart failure (HF) and arrhythmias:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – The clinical manifestations of LV systolic dysfunction induced by anthracycline exposure are similar to those observed in patients with other causes of HF and include dyspnea, fatigue, edema, orthopnea, and cardiogenic shock. The details on the clinical manifestations and diagnosis of HF are discussed separately. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palpitations or other signs of an arrhythmia</strong> –<strong> </strong>Patients may present with palpitations or other signs of an intermittent or sustained arrhythmia (eg, sudden death) [<a href="#rid2">2</a>]. In acute toxicity, atrial fibrillation may be a more common presentation than HF. For example, in a cohort of 1697 patients aged 18 to 75 years old receiving a doxorubicin-based regimen for lymphoma, 55 (3.2 percent) developed evidence of acute cardiotoxicity; among 44 cases reviewed in detail, the early manifestations of anthracycline toxicity included atrial fibrillation (n = 12), acute HF (n = 5), myocarditis (n = 2), and myocardial infarction (n = 1) [<a href="#rid3">3</a>]. Once anthracycline-associated cardiomyopathy is diagnosed, arrhythmias do not appear to be more common than in other causes of cardiomyopathy [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong> – Patients with anthracycline cardiotoxicity may undergo testing that reveals an elevated troponin, an elevated B-type natriuretic peptide (BNP), or decreased LV systolic or diastolic function.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systolic dysfunction</strong> – Patients who present with abnormal LV systolic function as the result of routine screening may be symptomatic or asymptomatic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diastolic dysfunction</strong> – After anthracyclines, some studies have reported subclinical diastolic dysfunction [<a href="#rid5">5-8</a>], HF with preserved ejection fraction, or restrictive cardiomyopathy [<a href="#rid9">9-11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elevated troponin</strong> – Anthracycline exposure does not primarily lead to acute myocardial infarction, myocarditis, or pericarditis. However, in prospective studies, elevated troponin levels or evidence of myocardial injury occurred in up to 30 percent of patients [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elevated BNP</strong> – In a patient with ongoing or remote anthracycline exposure, an elevation in BNP levels may be a sign of ventricular dysfunction caused by anthracyclines [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolonged QT interval</strong> – Prolongation of the QT interval (ie, QTc) is a rare manifestation of anthracycline toxicity [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H3560570076"><span class="h2">Time course of presentation</span><span class="headingEndMark"> — </span>The available evidence suggests that anthracycline-induced injury to the heart occurs during exposure and evolves over time [<a href="#rid16">16</a>]. In our experience, HF and arrhythmias can manifest acutely (within weeks of exposure), while most patients who present in the months to years after anthracycline exposure present with HF and complications of LV systolic dysfunction (eg, congestion, cardiogenic shock).</p><p>Further details on the mechanisms of anthracycline toxicity and the time course of injury can be found separately. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Mechanisms and time course of cardiotoxicity'</a>.)</p><p class="headingAnchor" id="H1218012700"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3653613251"><span class="h2">When to suspect anthracycline cardiotoxicity</span><span class="headingEndMark"> — </span>The diagnosis of anthracycline cardiotoxicity is typically suspected in one of the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Presentation with symptoms of HF, an arrhythmia, or another cardiac abnormality during or remote from anthracycline exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of reduced systolic function with routine monitoring during or after anthracycline treatment. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Monitoring during and after treatment'</a>.)</p><p></p><p class="headingAnchor" id="H111324243"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>In patients who present with signs or symptoms of potential cardiotoxicity during or remote from anthracycline therapy, a complete cardiac assessment is required. The initial assessment should include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focused history and physical examination</strong> – Each patient should undergo a history and physical examination with a focus on cardiovascular risk factors or preexisting cardiovascular disease (eg, coronary artery disease, atrial fibrillation, echocardiographic abnormalities).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anthracycline exposure history</strong> – We obtain a detailed history of anthracycline exposure that includes the specific agent(s), cumulative dose, the age at which the anthracycline was administered, and method of delivery (eg, infusional versus bolus). The specific risk factors for anthracycline toxicity are described elsewhere. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exposure to other cardiotoxic cancer therapies</strong> – Other cancer therapies can cause or exacerbate cardiotoxicity. Thus, we obtain a detailed history of exposure to other potentially cardiotoxic cancer therapies such as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Radiation to the chest. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a> and  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Human epidermal growth factor receptor 2 (HER2)-targeted therapies (eg, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>). (See  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a>. (See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Cyclophosphamide'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fluoropyrimidine agents. (See  <a class="medical medical_review" href="/d/html/89348.html" rel="external">"Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical manifestations, mechanisms, and management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protein kinase inhibitors. (See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ECG</strong> – We obtain an electrocardiogram (ECG) to evaluate for conduction system abnormalities (eg, QTc prolongation, arrhythmias such as atrial fibrillation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiography</strong> – If not already performed, we obtain a complete echocardiogram with use of echo contrast as appropriate. (See  <a class="medical medical_review" href="/d/html/5301.html" rel="external">"Contrast echocardiography: Contrast agents, safety, and imaging technique"</a>.)</p><p></p><p class="headingAnchor" id="H1625345248"><span class="h2">Additional diagnostic testing</span><span class="headingEndMark"> — </span>Following the initial evaluation, additional testing is only required in scenarios where the results of initial evaluation are not definitive (eg, nondiagnostic echocardiography images) or there is a clinical need to differentiate anthracycline-related cardiotoxicity from other potential causes of cardiac disease (eg, coronary artery disease, alcohol-induced LV dysfunction).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected systolic dysfunction with nondiagnostic images</strong> – In patients suspected of anthracycline toxicity in whom the results of echocardiography are not definitive, cardiovascular magnetic resonance (CMR) imaging or, much less commonly, nuclear quantification of LV ejection fraction (LVEF) can be used to identify the presence of LV dysfunction. The advantages and limitations of these tests are described elsewhere. (See  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a>.)</p><p></p><p class="bulletIndent1">The role of CMR imaging (eg, detection and quantification of myocardial edema and fibrosis) for the diagnosis of anthracycline-induced cardiotoxicity has not been established but has been described [<a href="#rid17">17</a>]. Several studies suggest that CMR may detect abnormal myocardial tissue characteristics and regional myocardial dysfunction following anthracycline therapy in patients with normal global systolic function [<a href="#rid18">18-20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with borderline evidence of systolic dysfunction</strong> – In patients who have a decrease in LVEF that does not meet criteria for diagnosis of anthracycline cardiomyopathy or who have other signs of LV systolic dysfunction (eg, decreased or low global longitudinal strain) without a decrease in LVEF, serial testing with echocardiography should be obtained. The formal criteria for anthracycline-associated LV dysfunction are discussed elsewhere in this topic. (See <a class="local">'Anthracycline-associated left ventricular dysfunction'</a> below.)</p><p></p><p class="bulletIndent1">In such patients with borderline evidence of LV dysfunction, we recommend repeat testing no later than at the end of the next cycle of planned anthracycline-containing chemotherapy or, if the patient is no longer receiving an anthracycline, approximately four weeks from the initial test.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation identifies other causes of myocardial injury</strong> – In patients with suspected anthracycline cardiotoxicity whose evaluation identifies other causes of LV dysfunction, further testing may be required to confirm or exclude the presence of anthracycline cardiotoxicity. Some patients may have multiple etiologies of LV dysfunction, such as other cancer therapies [<a href="#rid21">21</a>], infiltrative cardiomyopathies, or coronary artery disease.</p><p></p><p class="bulletIndent1">In patients for whom the presence or absence of anthracycline cardiotoxicity may alter management, an endomyocardial biopsy (EMB) can support the presence of anthracycline cardiomyopathy. The pathologic appearance of anthracycline cardiotoxicity includes the findings of myocardial edema, fibrosis, myofibrillar loss, and vacuolization [<a href="#rid22">22,23</a>]. However, EMB is an invasive test, and the pathologic findings of anthracycline toxicity are nonspecific [<a href="#rid24">24</a>]. Thus, EMB is rarely used to diagnose anthracycline-induced cardiomyopathy; the diagnosis is generally made by history and noninvasive testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests not used for diagnosis</strong> – In patients suspected of anthracycline toxicity, we do not routinely measure troponin or B-type natriuretic peptide (BNP) levels or obtain CMR or stress images (eg, exercise stress) to diagnose anthracycline cardiotoxicity. However, these tests may help to confirm the diagnosis by suggesting the presence of myocardial injury consistent with anthracycline toxicity. Further information on the role of these tests to monitor for anthracycline cardiotoxicity can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Monitoring during and after treatment'</a>.)</p><p></p><p class="headingAnchor" id="H28461708"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H581026942"><span class="h2">Anthracycline-associated left ventricular dysfunction</span><span class="headingEndMark"> — </span>In a patient who has received anthracycline treatment, the diagnosis of anthracycline-associated LV dysfunction is confirmed when other causes of LV systolic dysfunction have been reasonably excluded and there is a decrease in LVEF by ≥10 percent from baseline to an LVEF less than the local laboratory’s lower range of normal for the test [<a href="#rid25">25,26</a>]. In most cases, the diagnosis of anthracycline-associated LV systolic dysfunction is a diagnosis of exclusion; other causes of LV dysfunction (eg, coronary artery disease, other toxicities) must be reasonably excluded. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In patients with smaller reductions in LVEF or a significant change in another measure of LV function (eg, a &gt;15 percent reduction in global longitudinal strain), cardiotoxicity may be present, and serial testing is suggested to detect a drop in LVEF. Clinicians should be aware of the limitations of the clinical diagnosis of anthracycline-induced cardiotoxicity, which relies upon the accurate detection of a decline in LVEF. In the absence of other signs of abnormal LV structure and function (eg, LV dilation, functional mitral regurgitation, HF symptoms), we advise repeat testing and judicious management before major decisions regarding cancer therapy are made. Smaller decreases of LV function can be misleading, as LV function is subject to factors that are transient, such as LV loading condition and the adrenergic state, as well as interpretive variation. (See  <a class="medical medical_review" href="/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function", section on 'Variability'</a>.)</p><p class="headingAnchor" id="H3908550776"><span class="h2">Other forms of cardiac injury</span><span class="headingEndMark"> — </span>Anthracycline cardiotoxicity may manifest in forms other than LV systolic dysfunction, such as a decrease in LV mass [<a href="#rid27">27</a>]. Data have consistently shown that significant cardiac injury or cardiotoxicity can occur without a reduction in LVEF [<a href="#rid24">24,28</a>]. For patients who develop diastolic dysfunction, arrhythmias, or other cardiac abnormalities following anthracycline exposure, there are no specific diagnostic criteria; a short interval between exposure to anthracycline and new onset of signs or symptoms of cardiac dysfunction are indicators of anthracycline-induced cardiotoxicity.</p><p class="headingAnchor" id="H1102376423"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Since criteria for the diagnosis of anthracycline-induced cardiomyopathy are nonspecific, alternative or concurrent causes of LV systolic dysfunction should be excluded. The differential diagnosis of anthracycline-associated LV systolic dysfunction includes the other causes of LV dysfunction  (<a class="graphic graphic_table graphicRef78298" href="/d/graphic/78298.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef52168" href="/d/graphic/52168.html" rel="external">table 2</a>). The history, specific signs and symptoms, ECG findings, echocardiographic features, or additional laboratory tests may suggest the presence of an alternative cause of LV dysfunction or cardiotoxicity. The approach to evaluating for other etiologies of LV systolic dysfunction is discussed separately. (See  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Determining the cause and severity of heart failure or cardiomyopathy'</a>.)</p><p>In patients with suspected anthracycline cardiotoxicity who present with arrhythmias, the differential diagnosis is broad and includes volume overload, occult infection, and electrolyte abnormalities. The specific causes of arrhythmias are specific to the observed rhythm abnormality and are discussed separately. (See  <a class="medical medical_review" href="/d/html/956.html" rel="external">"Paroxysmal atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a> and  <a class="medical medical_review" href="/d/html/994.html" rel="external">"Premature ventricular complexes: Clinical presentation and diagnostic evaluation", section on 'Mechanisms for PVCs'</a>.)</p><p class="headingAnchor" id="H3252762447"><span class="h1">MANAGEMENT OF SYSTOLIC DYSFUNCTION</span></p><p class="headingAnchor" id="H3826218093"><span class="h2">Patients currently receiving anthracyclines</span><span class="headingEndMark"> — </span>Once the diagnosis of anthracycline-induced LV systolic dysfunction is confirmed, we take the following steps (see <a class="local">'Anthracycline-associated left ventricular dysfunction'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cease anthracycline therapy</strong> – For most patients with confirmed anthracycline-induced LV systolic dysfunction who are currently receiving an anthracycline, we immediately discontinue anthracycline therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manage LV systolic dysfunction</strong> – The management of LV systolic dysfunction in patients with anthracycline-induced LV systolic dysfunction is similar to that for patients who have other causes of LV systolic dysfunction:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medical therapy</strong> – Therapy for anthracycline-induced LV dysfunction is similar to management of those with LV dysfunction caused by other etiologies. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p></p><p class="bulletIndent2">There are limited data on the efficacy of standard therapies for asymptomatic LV systolic dysfunction caused by anthracycline toxicity. Recovery of LV function was studied in a cohort of 2625 patients treated with anthracyclines in whom an echocardiogram was performed every three months during and after therapy [<a href="#rid29">29</a>]. In this study, patients who had a decrease in LVEF &gt;10 percent to &lt;50 percent (defining cardiotoxicity) were treated with a beta blocker and an angiotensin converting enzyme inhibitor. In the 226 (9 percent) patients with cardiotoxicity, 11 percent had complete recovery of LVEF (increase to baseline values), and 71 percent of patients had partial recovery (increase in &gt;5 points to &gt;50 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reassessment of LV function</strong> – In patients diagnosed with anthracycline-associated LV dysfunction, we repeat imaging after anthracycline cessation and initiation of medical therapy to assess for any improvement in LV function. Further assessment of LV function is individualized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess risk and benefit of rechallenge with anthracycline</strong> – The feasibility of continued anthracycline administration, if indicated, depends on the degree of cardiac toxicity, cancer stage, the availability and effectiveness of non-anthracycline-based regimens, and patient preference. In general, if continued systemic anticancer therapy is indicated, it is preferable to pursue a non-anthracycline-containing regimen.</p><p></p><p class="bulletIndent1">For patients who developed anthracycline cardiotoxicity but who have recovered systolic LV function, the question of whether to administer additional anthracycline is often relevant. If the benefits of anthracycline rechallenge outweigh the risk of additional toxicity, further anthracycline therapy may be reasonable. Features of patients with prior anthracycline cardiotoxicity in whom reexposure may be reasonable include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with recovery of LVEF with no residual symptoms after an anthracycline-free interval.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients for whom the best chance of survival or meaningful palliation from cancer requires anthracycline-based therapy.</p><p></p><p class="bulletIndent1">However, there are no high-quality studies to guide practice in this clinical scenario.</p><p></p><p class="bulletIndent1">If the patient will undergo reexposure to anthracycline therapy, we typically reevaluate LV function with echocardiography prior to each cycle of anthracycline administration and use strategies to reduce the toxicity of further anthracycline therapy. The strategies to reduce toxicity are outlined elsewhere. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p></p><p class="headingAnchor" id="H136230483"><span class="h2">Remote history of anthracycline exposure</span><span class="headingEndMark"> — </span>Patients with anthracycline-induced LV systolic dysfunction who have no need for ongoing cancer treatment are managed similarly to other patients with LV systolic dysfunction. The approach to management typically depends on the presence or absence of HF symptoms and is discussed separately. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p class="headingAnchor" id="H1359925538"><span class="h1">MANAGEMENT OF OTHER TOXICITIES</span></p><p class="headingAnchor" id="H893695085"><span class="h2">Arrhythmias</span><span class="headingEndMark"> — </span>Arrhythmias associated with anthracycline toxicity are typically treated with cessation of further anthracycline treatment and acute and chronic management of the arrhythmia. Rechallenge with anthracycline is individualized and is based on the clinical severity of the arrhythmia, cancer stage, and the availability of alternative anticancer treatments.</p><p class="headingAnchor" id="H3590875093"><span class="h2">Diastolic dysfunction</span><span class="headingEndMark"> — </span>The presence of new-onset diastolic dysfunction presents a challenge. Patients with diastolic dysfunction without symptoms may have toxicity, but withholding therapy in the large number of patients who have diastolic dysfunction would result in numerous patients not receiving optimal cancer therapy. Thus, a finding of new diastolic dysfunction does not alter the approach to chemotherapy.</p><p class="headingAnchor" id="H2652471939"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with clinical HF caused by anthracycline toxicity have similar survival when compared with patients with HF due to other causes [<a href="#rid30">30</a>]. There are limited data on the prognostic value of a low LVEF on the occurrence of subsequent HF or cardiac mortality. In a large, single-center study with 2285 subjects, 45 patients had a baseline LVEF below the lower limits of normal (LVEF of 52 percent in men and 54 percent in women), and 112 patients had an LVEF within 5 percent of the lower limits of normal [<a href="#rid31">31</a>]. Baseline LVEF below the lower limits of normal or an LVEF within 5 percent of the lower limits of normal was predictive of HF and cardiac death; each 5 percent decrement in LVEF predicted a 40 percent greater risk of developing HF or cardiac death.</p><p>The details of determining the prognosis in patients with HF can be found separately. (See  <a class="medical medical_review" href="/d/html/3501.html" rel="external">"Prognosis of heart failure"</a>.)</p><p class="headingAnchor" id="H2435400478"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of anthracycline toxicity are primarily those of heart failure (HF) and arrhythmias. (See <a class="local">'Specific presentations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to suspect anthracycline cardiotoxicity</strong> – The diagnosis of anthracycline cardiotoxicity is typically suspected in one of the following scenarios:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Presentation with symptoms of HF, an arrhythmia, or another cardiac abnormality during or remote from anthracycline exposure.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Detection of reduced systolic function with routine monitoring during or after anthracycline treatment. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Monitoring during and after treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial testing</strong> – In patients who present with signs or symptoms of potential cardiotoxicity during or remote from anthracycline therapy, we obtain a focused history and physical examination, anthracycline exposure history, history of exposure to other cardiotoxic cancer therapies, ECG, and echocardiogram.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing</strong> –<strong> </strong>Following the initial evaluation, additional testing is only required in scenarios where the results of initial evaluation are not definitive. Common scenarios include (see <a class="local">'Additional diagnostic testing'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Suspected systolic dysfunction with nondiagnostic images</p><p class="bulletIndent3"><span class="glyph">-</span>Patients with borderline evidence of systolic dysfunction</p><p class="bulletIndent3"><span class="glyph">-</span>Evaluation identifies other causes of myocardial injury</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anthracycline-associated left ventricular dysfunction</strong> –<strong> </strong>In a patient who has received anthracycline treatment, the diagnosis of anthracycline-associated left ventricular (LV) dysfunction is confirmed when other causes of LV systolic dysfunction have been reasonably excluded and there is a decrease in LV ejection fraction (LVEF) by ≥10 percent from baseline to an LVEF less than the local laboratory’s lower range of normal for that test. (See <a class="local">'Anthracycline-associated left ventricular dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other forms of cardiac injury</strong> – Anthracycline cardiotoxicity may manifest in a form other than LV systolic dysfunction; it includes any toxicity to the heart that results in an abnormal structural or functional change (eg, arrhythmias). (See <a class="local">'Other forms of cardiac injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> –<strong> </strong>Since criteria for the diagnosis of anthracycline-induced cardiomyopathy are nonspecific, alternative or concurrent causes of LV systolic dysfunction should be excluded  (<a class="graphic graphic_table graphicRef78298" href="/d/graphic/78298.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef52168" href="/d/graphic/52168.html" rel="external">table 2</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of anthracycline-associated systolic dysfunction</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients currently receiving therapy</strong> – Once the diagnosis of anthracycline-induced LV systolic function is confirmed in a patient currently receiving anthracycline therapy, we take the following steps (see <a class="local">'Patients currently receiving anthracyclines'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cease anthracycline therapy</strong> – For most patients with confirmed anthracycline-induced LV systolic dysfunction who are currently receiving an anthracycline, we immediately discontinue anthracycline therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Manage LV systolic dysfunction</strong> – Therapy for anthracycline-induced LV dysfunction is similar to management of those with LV dysfunction caused by other etiologies. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p></p><p class="bulletIndent3">In patients diagnosed with anthracycline-associated LV dysfunction, we repeat imaging in one to two weeks after anthracycline cessation to assess for recovery. Further assessment of LV dysfunction is individualized.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Assess risk and benefit of rechallenge with anthracycline</strong> – In general, if continued systemic anticancer therapy is indicated, it is preferable to pursue a non-anthracycline-containing regimen.</p><p></p><p class="bulletIndent3">For patients who developed anthracycline cardiotoxicity but who have recovered systolic LV function, the question of whether to administer additional anthracycline is often relevant.</p><p></p><p class="bulletIndent3">If the patient will undergo reexposure to anthracycline therapy, we typically reevaluate LV function with echocardiography prior to each cycle of anthracycline administration and use strategies to reduce the toxicity of further anthracycline therapy. The strategies to reduce toxicity are outlined elsewhere. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Remote history of anthracycline exposure</strong> – Patients with anthracycline-induced LV systolic dysfunction who have no need for ongoing cancer treatment are managed similarly to other patients with LV systolic dysfunction. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of other toxicities</strong> – Arrhythmias associated with anthracycline toxicity are typically treated with cessation of further anthracycline treatment and with acute and chronic management of the arrhythmia. (See <a class="local">'Arrhythmias'</a> above.)</p><p></p><p class="bulletIndent1">The finding of new diastolic dysfunction does not alter the approach to chemotherapy. (See <a class="local">'Diastolic dysfunction'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012; 126:2749.</a></li><li><a class="nounderline abstract_t">Essa H, Wright DJ, Dobson R, Lip GYH. Chemotherapy-Induced Arrhythmia - Underrecognized and Undertreated. Am J Med 2021; 134:1224.</a></li><li><a class="nounderline abstract_t">Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112:3754.</a></li><li><a class="nounderline abstract_t">Mazur M, Wang F, Hodge DO, et al. Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. JACC Clin Electrophysiol 2017; 3:139.</a></li><li><a class="nounderline abstract_t">Stoodley PW, Richards DA, Boyd A, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging 2013; 14:228.</a></li><li><a class="nounderline abstract_t">Moon TJ, Miyamoto SD, Younoszai AK, Landeck BF. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy. Cardiol Young 2014; 24:854.</a></li><li><a class="nounderline abstract_t">Bayram C, Çetin İ, Tavil B, et al. Evaluation of cardiotoxicity by tissue Doppler imaging in childhood leukemia survivors treated with low-dose anthracycline. Pediatr Cardiol 2015; 36:862.</a></li><li><a class="nounderline abstract_t">Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging 2020; 13:198.</a></li><li><a class="nounderline abstract_t">Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267.</a></li><li><a class="nounderline abstract_t">Guendouz S, Buicuic O, Kirsch M, et al. Restrictive cardiomyopathy associated with left ventricle and left atria endocardial calcifications following chemotherapy. J Am Coll Cardiol 2011; 57:1633.</a></li><li><a class="nounderline abstract_t">Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 1986; 55:274.</a></li><li><a class="nounderline abstract_t">Kitayama H, Kondo T, Sugiyama J, et al. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer 2017; 24:774.</a></li><li><a class="nounderline abstract_t">Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109:2749.</a></li><li><a class="nounderline abstract_t">Lu X, Zhao Y, Chen C, et al. BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer. Oncol Lett 2019; 18:4992.</a></li><li><a class="nounderline abstract_t">Arbel Y, Swartzon M, Justo D. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs 2007; 18:493.</a></li><li><a class="nounderline abstract_t">Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med 2020; 7:26.</a></li><li class="breakAll">Hundley WG, Bluemke DA, Finn JP, et al. In: ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Lippincott Williams &amp; Wilkins, Baltimore 2010. p.2462.</li><li><a class="nounderline abstract_t">Toro-Salazar OH, Gillan E, O'Loughlin MT, et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013; 6:873.</a></li><li><a class="nounderline abstract_t">Mawad W, Mertens L, Pagano JJ, et al. Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors. Eur Heart J Cardiovasc Imaging 2021; 22:435.</a></li><li><a class="nounderline abstract_t">Harries I, Berlot B, Ffrench-Constant N, et al. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction. Int J Cardiol 2021; 343:180.</a></li><li><a class="nounderline abstract_t">Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018; 71:1755.</a></li><li><a class="nounderline abstract_t">Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978; 240:1603.</a></li><li><a class="nounderline abstract_t">Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986; 46:3722.</a></li><li><a class="nounderline abstract_t">Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984; 2:112.</a></li><li><a class="nounderline abstract_t">Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43:4229.</a></li><li><a class="nounderline abstract_t">Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 80:1560.</a></li><li><a class="nounderline abstract_t">Jordan JH, Castellino SM, Meléndez GC, et al. Left Ventricular Mass Change After Anthracycline Chemotherapy. Circ Heart Fail 2018; 11:e004560.</a></li><li><a class="nounderline abstract_t">Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014; 63:809.</a></li><li><a class="nounderline abstract_t">Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131:1981.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015; 65:2511.</a></li><li><a class="nounderline abstract_t">Wang L, Tan TC, Halpern EF, et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol 2015; 116:442.</a></li></ol></div><div id="topicVersionRevision">Topic 90854 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212997" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34216562" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chemotherapy-Induced Arrhythmia - Underrecognized and Undertreated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330681" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759386" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782955" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24044518" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577226" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation of cardiotoxicity by tissue Doppler imaging in childhood leukemia survivors treated with low-dose anthracycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31542526" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995091" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474043" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Restrictive cardiomyopathy associated with left ventricle and left atria endocardial calcifications following chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3456785" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28434150" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148277" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612011" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17351403" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32258060" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cardiotoxicity of Anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32258060" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiotoxicity of Anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24097420" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32535624" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454967" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567210" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/691145" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3458531" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6699662" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017568" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36229093" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29991488" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Left Ventricular Mass Change After Anthracycline Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24291281" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25948538" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26071994" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
